<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tissue inhibitors of metalloproteinases (TIMPs) have been shown to be multifunctional factors </plain></SENT>
<SENT sid="1" pm="."><plain>Contrasting with their enzyme-inhibitory activity, TIMPs also promote cell growth </plain></SENT>
<SENT sid="2" pm="."><plain>Previously, we have reported an enhanced expression of TIMP-1 by <z:mpath ids='MPATH_458'>normal</z:mpath> reactive B cells and high-grade <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, a series of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines were analyzed for their expression of TIMP-1 </plain></SENT>
<SENT sid="4" pm="."><plain>TIMP-1 expression correlates with upregulation of activation and survival markers </plain></SENT>
<SENT sid="5" pm="."><plain>TIMP-1-negative cells express the phenotype associated with group I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines and Epstein-Barr virus (EBV)-negative, nonendemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> (CD10+, CD38+, sIg+, and CD77+) </plain></SENT>
<SENT sid="6" pm="."><plain>However, TIMP-1+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines showed group II/III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> phenotype, downregulation of the above markers, and upregulation and secretion of the activation marker CD23 </plain></SENT>
<SENT sid="7" pm="."><plain>Also, TIMP-1+ cells have high levels of CD40 expression </plain></SENT>
<SENT sid="8" pm="."><plain>To determine whether TIMP-1 is directly involved in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> phenotype, an EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> line JD38 was infected with timp-1-expressing retrovirus and analyzed </plain></SENT>
<SENT sid="9" pm="."><plain>In the absence of EBV, upregulation of TIMP-1 is sufficient to induce the same phenotype seen in TIMP-1+, EBV+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines (CD10-, CD38-, sIg-, CD77-, CD23+, CD40 bright) </plain></SENT>
<SENT sid="10" pm="."><plain>This study not only suggests a role for TIMP-1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>, but also supports its value as a prognostic factor </plain></SENT>
<SENT sid="11" pm="."><plain>This is a US government work </plain></SENT>
<SENT sid="12" pm="."><plain>There are no restrictions on its use </plain></SENT>
</text></document>